Ingmar Gorman, Chief Executive Officer and Co-Founder

Professional Overview

Ingmar Gorman is an accomplished executive and researcher with extensive expertise in the field of psychedelic-assisted therapies. As the Chief Executive Officer and Co-Founder of Fluence, he leverages his deep understanding of the latest advancements in this emerging industry to drive innovation and promote the responsible use of psychedelics for therapeutic purposes.

Experience Summary

Current Role

As the CEO and Co-Founder of Fluence, Ingmar is responsible for leading the company's strategic vision, overseeing its operations, and fostering collaborative partnerships within the psychedelic research and clinical communities. Under his leadership, Fluence has established itself as a prominent player in the field, contributing to the development of evidence-based protocols and advocating for the safe and ethical use of psychedelics in healthcare.

Career Progression

Ingmar's career has been marked by his dedication to advancing the understanding and application of psychedelic-assisted therapies. Prior to his current role, he served as the Chair of the Scientific Advisory Board at Journey Clinical Inc. and held various positions at the Multidisciplinary Association for Psychedelic Studies (MAPS), including Clinical Investigator, Site Co-Principle Investigator, and Co-Investigator. Ingmar also gained valuable experience as a Psychologist at the Center for Optimal Living and as an NIH Postdoctoral Fellow at New York University.

Academic Background

Ingmar holds a Doctoral Degree in Psychology from The New School, where he specialized in the study of psychedelic-assisted therapies. He also completed an NIH Postdoctoral Fellowship in Behavioral Sciences Training in Drug Abuse Research at New York University, further expanding his expertise in this field. Ingmar's academic achievements and research contributions have positioned him as a respected voice in the psychedelic research community.

Areas of Expertise

Psychedelic-assisted therapies: Ingmar has a deep understanding of the clinical applications and therapeutic potential of psychedelics, including the use of substances such as MDMA, psilocybin, and ketamine in the treatment of mental health conditions.

Clinical research and protocol development: Ingmar's experience as a clinical investigator and site co-principle investigator has provided him with extensive knowledge in designing and implementing rigorous research studies to evaluate the safety and efficacy of psychedelic-assisted therapies.

Regulatory and ethical considerations: Ingmar is well-versed in the complex legal and regulatory landscape surrounding the use of psychedelics, as well as the ethical considerations that must be addressed in the development and deployment of these treatments.

Collaborative leadership: As a co-founder, Ingmar has demonstrated his ability to build and lead cross-functional teams, fostering a culture of innovation and problem-solving within the Fluence organization.

Professional Impact

Throughout his career, Ingmar has made significant contributions to advancing the field of psychedelic-assisted therapies. His work has been instrumental in expanding the understanding of the therapeutic potential of these substances, and he has played a crucial role in the development of evidence-based protocols and the promotion of safe and ethical practices in the industry. Ingmar's leadership and expertise have had a tangible impact on the lives of patients seeking alternative, evidence-based treatments for mental health conditions.

Conclusion

Ingmar Gorman's impressive track record as a pioneering researcher, clinical investigator, and seasoned executive in the psychedelic industry positions him as a valuable asset to Fluence and the broader psychedelic healthcare ecosystem. His unwavering commitment to advancing the responsible use of psychedelics for therapeutic purposes and his proven ability to drive innovation make him a key figure in shaping the future of this rapidly evolving field.